Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher Wednesday after the company reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of Alzheimer’s disease dementia. The Details: The top-line results showed no decline in cognition scores in patients with mild Alzheimer’s disease who received simufilam continuously for 24 months. “We’re fighting Alzheimer’s disease by testing simufilam, a new type of drug that has a completely different mechanism of action from monoclonal antibody drug treatments,” said Re…

Read More